Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates Journal Article
| Authors: | Ajkunic, A.; Sayar, E.; Roudier, M. P.; Patel, R. A.; Coleman, I. M.; De Sarkar, N.; Hanratty, B.; Adil, M.; Zhao, J.; Zaidi, S.; True, L. D.; Sperger, J. M.; Cheng, H. H.; Yu, E. Y.; Montgomery, R. B.; Hawley, J. E.; Ha, G.; Persse, T.; Galipeau, P.; Lee, J. K.; Harmon, S. A.; Corey, E.; Lang, J. M.; Sawyers, C. L.; Morrissey, C.; Schweizer, M. T.; Gulati, R.; Nelson, P. S.; Haffner, M. C. |
| Article Title: | Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates |
| Abstract: | Therapeutic approaches targeting proteins on the surface of cancer cells have emerged as an important strategy for precision oncology. To capitalize on the potential impact of drugs targeting surface proteins, detailed knowledge about the expression patterns of the target proteins in tumor tissues is required. In castration-resistant prostate cancer (CRPC), agents targeting prostate-specific membrane antigen (PSMA) have demonstrated clinical activity. However, PSMA expression is lost in a significant number of CRPC tumors. The identification of additional cell surface targets is necessary to develop new therapeutic approaches. Here, we performed a comprehensive analysis of the expression heterogeneity and co-expression patterns of trophoblast cell-surface antigen 2 (TROP2), delta-like ligand 3 (DLL3), and carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) in CRPC samples from a rapid autopsy cohort. We show that DLL3 and CEACAM5 exhibit the highest expression in neuroendocrine prostate cancer (NEPC), while TROP2 is expressed across different CRPC molecular subtypes, except for NEPC. We further demonstrated that AR alterations were associated with higher expression of PSMA and TROP2. Conversely, PSMA and TROP2 expression was lower in RB1-altered tumors. In addition to genomic alterations, we show a tight correlation between epigenetic states, particularly histone H3 lysine 27 methylation (H3K27me3) at the transcriptional start site and gene body of TACSTD2 (encoding TROP2), DLL3, and CEACAM5, and their respective protein expression in CRPC patient-derived xenografts. Collectively, these findings provide insights into patterns and determinants of expression of TROP2, DLL3, and CEACAM5 with implications for the clinical development of cell surface targeting agents in CRPC. © The Author(s) 2024. |
| Keywords: | immunohistochemistry; controlled study; human tissue; protein expression; unclassified drug; gene locus; genetic transcription; membrane antigen; prostate specific membrane antigen; epigenetics; histone h3; androgen receptor; lysine; castration resistant prostate cancer; cell surface; tumor microenvironment; histone methylation; metastatic prostate cancer; human; male; article; genetic background; delta like ligand 3; trophoblast cell surface antigen 2; carcinoembryonic antigen related cell adhesion molecule 5; neuroendocrine carcinoma of the prostate |
| Journal Title: | npj Precision Oncology |
| Volume: | 8 |
| ISSN: | 2397-768X |
| Publisher: | Springer Nature |
| Date Published: | 2024-05-17 |
| Start Page: | 104 |
| Language: | English |
| DOI: | 10.1038/s41698-024-00599-6 |
| PROVIDER: | scopus |
| PMCID: | PMC11101486 |
| PUBMED: | 38760413 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work